The Biotech Rollercoaster Ride: From Lab To Buyout
Caixa Capital Risc's Pablo Cironi On Sanifit's Story
Executive Summary
After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.
You may also be interested in...
Spain Biotech Boost As Minoryx Raises €21m
Spain's biotech start-ups are building an impressive pipeline of drugs but have found financing a challenge, so news of fresh funds for rare diseases group Minoryx has been cheered by the sector.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.